These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 24168783

  • 1. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.
    Katsaros KM, Kastl SP, Krychtiuk KA, Hutter R, Zorn G, Maurer G, Huber K, Wojta J, Christ G, Speidl WS.
    EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783
    [Abstract] [Full Text] [Related]

  • 2. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP, Xu WT, Wang L, Li H, Shao CL, Gu HB, Chan SP, Xu HF, Yang XJ.
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [Abstract] [Full Text] [Related]

  • 3. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9.
    Katsaros KM, Kastl SP, Zorn G, Maurer G, Wojta J, Huber K, Christ G, Speidl WS.
    JACC Cardiovasc Interv; 2010 Jan; 3(1):90-7. PubMed ID: 20129576
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M, Pross V, Marx N, Hoffmann R.
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [Abstract] [Full Text] [Related]

  • 5. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K, Mehilli J, Byrne RA, Schulz S, Massberg S, Laugwitz KL, Vorpahl M, Seyfarth M, Kastrati A, ISAR-LEFT MAIN Study Investigators.
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [Abstract] [Full Text] [Related]

  • 6. Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents.
    Yin J, Shen L, Ji M, Wu Y, Cai S, Chen J, Yao Z, Ge J.
    Biomed Res Int; 2017 Jan; 2017():8730271. PubMed ID: 28373989
    [Abstract] [Full Text] [Related]

  • 7. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
    Zeng M, Yan X, Wu W.
    BMC Cardiovasc Disord; 2021 Sep 17; 21(1):446. PubMed ID: 34535088
    [Abstract] [Full Text] [Related]

  • 8. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M, Schröder J, Pross V, Marx N, Hoffmann R.
    Catheter Cardiovasc Interv; 2014 May 01; 83(6):881-7. PubMed ID: 23765557
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic value of myocardial SPECT to detect in-stent restenosis after drug-eluting stent implantation.
    Park HE, Koo BK, Park KW, Paeng JC, Lee HY, Kang HJ, Kim HS.
    Int J Cardiovasc Imaging; 2012 Dec 01; 28(8):2125-34. PubMed ID: 22395666
    [Abstract] [Full Text] [Related]

  • 10. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG, Kang SJ, Ahn JM, Kim WJ, Lee JY, Park DW, Lee SW, Kim YH, Lee CW, Park SW, Park SJ.
    Catheter Cardiovasc Interv; 2014 May 01; 83(6):873-8. PubMed ID: 22815193
    [Abstract] [Full Text] [Related]

  • 11. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL, Ye F, Zhang JJ, Zou JJ, Qian XS, Li F, Yang S, Ge Z, Shan SJ, Li XB, Xu T, Kan J, Lin L, Han YL.
    Cardiovasc Ther; 2013 Aug 01; 31(4):193-200. PubMed ID: 22954234
    [Abstract] [Full Text] [Related]

  • 12. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K, Li YJ, Gao S.
    Coron Artery Dis; 2015 May 01; 26(3):220-4. PubMed ID: 25647458
    [Abstract] [Full Text] [Related]

  • 13. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H, Maehara A, Mintz GS, Yu A, Wang H, Mandinov L, Popma JJ, Ellis SG, Grube E, Dawkins KD, Weissman NJ, Turco MA, Ormiston JA, Stone GW.
    JACC Cardiovasc Interv; 2009 Dec 01; 2(12):1269-75. PubMed ID: 20129555
    [Abstract] [Full Text] [Related]

  • 14. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a.
    Speidl WS, Katsaros KM, Kastl SP, Zorn G, Huber K, Maurer G, Wojta J, Christ G.
    Atherosclerosis; 2010 Jan 01; 208(1):285-9. PubMed ID: 19683238
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study.
    Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B.
    EuroIntervention; 2015 Dec 01; 11(8):926-34. PubMed ID: 25169589
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P, RESOLUTE All Comers, RESOLUTE International Investigators.
    JACC Cardiovasc Interv; 2013 Sep 01; 6(9):905-13. PubMed ID: 23954063
    [Abstract] [Full Text] [Related]

  • 17. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
    Habara S, Iwabuchi M, Inoue N, Nakamura S, Asano R, Nanto S, Hayashi Y, Shiode N, Saito S, Ikari Y, Kimura T, Hosokawa J, Nakamura M, Kotani J, Kozuma K, Mitsudo K.
    Am Heart J; 2013 Sep 01; 166(3):527-33. PubMed ID: 24016503
    [Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: a report from the National Cardiovascular Data Registry.
    Kutcher MA, Brennan JM, Rao SV, Dai D, Anstrom KJ, Mustafa N, Sedrakyan A, Booth ME, Douglas PS, Messenger JC.
    Catheter Cardiovasc Interv; 2014 Feb 01; 83(2):171-81. PubMed ID: 23907981
    [Abstract] [Full Text] [Related]

  • 19. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
    Wang G, Sun Z, Jin Q, Xu K, Li Y, Wang X, Ma Y, Liu H, Zhao X, Wang B, Deng J, Guan S, Ge M, Wang X, Xu B, Han Y.
    Catheter Cardiovasc Interv; 2015 Mar 01; 85 Suppl 1():744-51. PubMed ID: 25630447
    [Abstract] [Full Text] [Related]

  • 20. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
    Shen Y, Li C, Zhang RY, Zhang Q, Shen WF, Ding FH, Lu L.
    Int J Cardiol; 2017 Feb 01; 228():129-136. PubMed ID: 27863353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.